News

Year 

MSN Group Receives ANDA Approval for Dimethyl Fumarate Capsules

Hyderabad, 7th October 2020:MSN Group (MSN), India’s leading integrated pharmaceutical company, receives ANDA approval for Dimethyl Fumarate delayed release capsule. The active pharmaceutical ingredient as well as the finished formulation of Dimethyl Fumarate Delayed-Release Capsules are manufactured in-house at MSN’s manufacturing facilities. MSN has entered into a commercial partnership with Dr Reddy’s for marketing the product in the United States of America. The medicine will be available in strengths of 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Dimethyl Fumarate is a prescription medicine used to treat relapsing forms of multiple sclerosis in Adults.

MSN currently has over 100 ANDAs & 710 DMFs and is world no 1 in Active US DMF Filings as per US FDA.


MSN Group introduces FAVILOW400 mg to reduce pill burden in COVID-19 treatment


  • MSN R&D Milestone by introducing increased strength of FAVILOW 400 mg
  • More relaxed dosage regime - half the number of pills
  • Extended shelf life of Favilow 200 mg from 3months to 6 months
  • Free home delivery in 170 plus cities
  • MSN COVID Helpline @ 91005 91030 / email to customercare@msnlabs.com

Hyderabad, 17th September 2020: MSN Group (MSN), India’s leading integrated pharmaceutical company, today introduced a 400 mg version of oral antiviral Favipiravir FAVILOW which is most affordable brand, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day. The shelf life of the FAVILOW 200 mg is extended from 3 months to 6 months which would improve pharmacies confidence in stocking the product and ease out availability of the medicine to patients.

Earlier in August, MSN has come up with the world’s most affordable Favipiravir, under the brand name FAVILOW. Priced at 33 INR, FAVILOW 200 mg was made available to patients requiring treatment in pharmacies across 170 plus cities. In order to reduce the pill burden and the overall treatment outcome, MSN has come up with introduction of FAVILOW 400 mg.

Explaining on the significant development of coming up with higher strength of FAVILOW, Dr. MSN Reddy, CMD – MSN Group, said “We have launch the most affordable Favipiravir in order to reduce the cost burden. We continue to harness our expertise in research & innovation by coming up with treatment options for patients battling Covid 19. Our effort of introducing the higher strength of FAVILOW is to reduce the daily pill burden.”

The higher strength of FAVILOW stands as yet another milestone effort by MSN’s in-house R&D. As part of the COVID 19 treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ’’OSELOW’’.

FAVILOW 400 will be available at all the major medical and hospital pharmacies and can be purchased by producing a prescription by a healthcare practitioner at the pharmacies. For availability & home delivery of the medicine, please contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com



MSN Group announces Free FAVILOW tablets to all the COVID19 front-line fighters


  • FAVILOW Free for covid19 Front line fighters
  • Free home delivery in 170 plus cities
  • MSN COVID Helpline @ 91005 91030 / email to customercare@msnlabs.com

Hyderabad, 31st August 2020: MSN Group (MSN), India’s leading integrated pharmaceutical company, announced free FAVILOW tablets to all the brave hearts, including doctors, nurses, journalists, police & sanitation personnel across 170 cities who have been tested positive for COVID 19 while performing their duty to contain the spread of the virus.

The COVID19 pandemic has claimed the lives of thousands but has failed to crush the indomitable spirit of our Doctors, Nurses, Journalists, Police & sanitation personnel, who have put their lives at risk for our safety. MSN salutes these heroes and their service first-spirit by distributing free FAVILOW 200 Mg tablets (Favipiravir) as an attempt to salute their selfless spirit. This service will be active during the ongoing pandemic year of 2020.Doctors, Nurses, Journalists, Police & sanitation personnel can avail the benefit by providing the test report, doctor’s prescription and work ID at the customer care desk for free delivery of FAVILOW.

Dr MSN Reddy, CMD – MSN Group, commented “We want to express our solidarity to all the front-line fighters for displaying exemplary service during this pandemic situation. We feel as an organization it is our responsibility to acknowledge & to service all the Bravehearts. We have already introduced Favilow at most affordable prices in line with our commitment to reduce the cost burden in treatment of covid 19.”

“The gesture of MSN to Doctors & healthcare workers is unprecedented and exemplary. Indian Medical Association (IMA) acknowledges & appreciates the gesture” says Dr. Rajan Sharma, Hon. National President and Dr. R.V. Asokan, Hon. Secretary General from IMA when informed about the initiative by team MSN.

The drug ‘Favipiravir’ has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalized with mild to moderate symptoms of the disease. FAVILOW (Favipiravir) is available at all the major medical and hospital pharmacies and can be purchased by producing a prescription by a healthcare practitioner at the outlet.

As part of the COVID 19 treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘’OSELOW’’.

For availability, please contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com


MSN Group announces free home delivery of FAVILOW in 170 cities


  • World’s most affordable Favipiravir at 33 INR
  • Free home delivery in 170 plus cities
  • MSN COVID Helpline @ 91005 91030 / email to customercare@msnlabs.com

Hyderabad, 21st August 2020: MSN Group (MSN), India’s leading integrated pharmaceutical company, announced free home delivery of FAVILOW to patients suffering with mild to moderate COVID-19 across 170 cities. FAVILOW is available with leading pharmacy and hospitals and MSN is partnering with retail pharmacies across India to facilitate delivery of FAVILOW to patients in need of them.

Priced at 33 INR, FAVILOW is the world’s most affordable Favipiravir produced by MSN Labs. FAVILOW is currently available in 200 mg dosage strength and MSN will soon be launching FAVILOW 400 mg in the market to reduce the pill burden.

Dr MSN Reddy, CMD – MSN Group, commented “We want our product FAVILOW, to be available across the country to patients in need of it. Our efforts to come up with home delivery of the medicine are to help the patients with easy availability. Our teams are actively working with pharmacies across the country to make this feat possible”.

The drug ‘Favipiravir’ has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalized with mild to moderate symptoms of the disease. FAVILOW (Favipiravir) is available at all the major medical and hospital pharmacies and can be purchased by producing a prescription by a healthcare practitioner at the outlet.

As part of the COVID 19 treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘’OSELOW’’.

For availability, please contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com



MSN Group launches ‘FAVILOW’ the most affordable Favipiravir in India for the treatment of Covid-19.


  • World’s most affordable Favipiravir
  • Cost 33 INR per tablet
  • Available in pharmacies across India
  • MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com

Hyderabad, 13th August 2020: MSN Group (MSN), India’s leading generic pharmaceutical company, announced today that it has launched the most affordable Favipiravir, marketed under the brand name ‘FAVILOW’. The medicine will be costing 33 INR with recommended dose being 200 mg and will be available in all the pharmacies across India.

MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW through its own in-house R&D team. The medicine can be used for the treatment of mild to moderate COVID-19 patients.

Dr MSN Reddy, CMD – MSN Group, commented “We are glad to launch our product FAVILOW, during current tough times as COVID 19 cases in India are increasing like never before. We as a company always believe that quality medicine has to be accessible and available to everyone. We are confident that our product will nurture hope in patients as it is both effective and affordable at the same time.

The drug ‘Favipiravir’ has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalized with severe symptoms of the disease. FAVILOW (Favipiravir) will be available in 200 mg tablets which have to be purchased at medical and hospital pharmacies with a prescription by a healthcare practitioner.

As part of the COVID treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘’OSELOW’’. MSN will also be launching FAVILOW 400 mg very soon in the market.

For availability, please contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com

What's new

CPhI Worldwide 2020
13th - 15th Oct'20

Know more 

Our ever-growing portfolio

We are extremely grateful for the wonderful family of clients and customers that we have built across the globe.

715

DMFs

370

APIs

90

CEPs

2000

DOSSIERs

200

FDFs

100

ANDAs